MiMedx GroupMDXG +3.01%57 Market Cap is $585.4 Mil as of Jun. 26, 2026. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.96 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,431 Biotechnology companies, MiMedx Group ranks better than 73.65% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). MiMedx Group's share price for the quarter that ended in Mar. 2026 was $3.95. MiMedx Group's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 148.9 Mil. Therefore, MiMedx Group's market cap for the quarter that ended in Mar. 2026 was $588.3 Mil.
MiMedx Group's quarterly market cap
declined
from Sep. 2025 ($1,033.6 Mil) to Dec. 2025 ($1,002.6 Mil) and
declined
from Dec. 2025 ($1,002.6 Mil) to Mar. 2026 ($588.3 Mil).
MiMedx Group's annual market cap
increased
from Dec. 2023 ($1,282.4 Mil) to Dec. 2024 ($1,413.5 Mil) but then
declined
from Dec. 2024 ($1,413.5 Mil) to Dec. 2025 ($1,002.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MiMedx Group's Enterprise Value for Today is $443.2 Mil.
MiMedx Group (NAS:MDXG) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
MiMedx Group Market Cap Related Terms
MiMedx Group Market Cap Historical Data
* Premium members only.
The historical data trend for MiMedx Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MiMedx Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Market Cap distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
MiMedx Group's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a Market Cap of $585.4 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MiMedx Group and its competitors. According to the industry distribution chart, MiMedx Group ranks #377 out of 1431 companies in the Biotechnology industry, placing it in the top 26.3%.
Is MiMedx Group's Market Cap too high?
MiMedx Group's current Market Cap is $585.4 Mil. The Biotechnology industry median Market Cap is 113.83. MiMedx Group's value of $585.4 Mil is 414.3% above this industry median. Based on the distribution chart, MiMedx Group ranks #377 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Market Cap compare to ASMB and AGMB?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #377 out of 1431 companies for Market Cap. This puts MiMedx Group in the upper half of its industry. The industry median Market Cap is 113.83. MiMedx Group's value of $585.4 Mil is 414.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current Market Cap of $585.4 Mil is 414.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MiMedx Group and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current Market Cap is $585.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.96, compared to a current price of $3.93 — trading 43.5% below its estimated fair value. The current Market Cap is $585.4 Mil and 414.3% above the Biotechnology industry median of 113.83. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Market Cap is $585.4 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $3.93 is trading 43.5% below its estimated GF Value™ of $6.96.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Market Cap: $585.4 Mil
GF Value™: $6.96 vs. price of $3.93 (43.5% below fair value)
Industry Position: 414.3% above the Biotechnology median (#377 of 1431)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
